Advertisement

Anti-Inflammatory Treatment in Chronic Back Pain

  • I. Z. GaydukovaEmail author
  • D. M. Bichurina
  • Yu. R. Popova
  • A. P. Rebrov
Article
  • 2 Downloads

Objectives. To analyze the causes of the non-use of nonsteroidal anti-inflammatories (NSAID) and discontinuation of previously used NSAID treatment in patients with chronic nonspecific back pain (CBP). Materials and methods. Treatment was analyzed in 250 patients with CBP initially and at one and two years. Results and conclusions. A total of 52 CBP patients (20.8%) did not receive NSAID, 38 patients (15.2%) consistently received NSAID frequently (on four or more days per week), 44 patients (17.6%) received NSAID consistently at low frequency (on three or fewer days per week), 62 patients (24.8%) received courses of NSAID, and 54 (21.6%) received NSAID as needed. The absence of NSAID treatment in CBP was associated with older age, the presence of comorbid states, nonalcoholic fatty liver disease, and obesity. Discontinuation of previously used NSAID was equally linked with resolution of pain and the failure to respond to treatment, with excess body weight, and use of nonselective NSAID. Continuation of effective anti-inflammatory treatment was associated with the use of coxibs, use of Neurobion, normal body weight, and achievement of reductions in pain syndrome even if complete resolution was not attained. Increases in treatment compliance could be achieved by increasing efficacy by using NSAID (especially coxibs) in complex with group B vitamins (B1, B6, B12), normalization of body mass index, and effective control of liver function.

Keywords

chronic back pain non-steroidal anti-inflammatory drugs treatment compliance nonalcoholic fatty liver disease obesity Neurobion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. Shmagel, R. Foley, and H. Ibrahim, “Epidemiology of chronic low back pain in US adults: Data from the 2009–2010 National Health and Nutrition Examination Survey,” Arthritis Care Res (Hoboken), 68, No. 11, 1688–1694 (2016),  https://doi.org/10.1002/acr.22890.CrossRefGoogle Scholar
  2. 2.
    H. Breivik, B. Collett, V. Ventafridda, and D. Gallacher, “Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment,” Eur. J. Pain, 10, No. 4, 287–333 (2006),  https://doi.org/10.1016/j.ejpain.2005.06.009.CrossRefGoogle Scholar
  3. 3.
    B. G. Peng, “Pathophysiology, diagnosis, and treatment of discogenic low back pain,” World J. Orthop., 4, No. 2, 42–52 (2013),  https://doi.org/10.5312/wjo.v4.i2.42.CrossRefGoogle Scholar
  4. 4.
    V. K. Podichetty, “The aging spine: the role of inflammatory mediators in intervertebral disc degeneration,” Cell. Mol. Biol. (Noisy-legrand), 53, No. 5, 4–18 (2007).Google Scholar
  5. 5.
    R. Deyo, S. Mirza, J. Turner, and B. Martin, “Overtreating chronic back pain: time to back off?” J. Am. Board Fam. Med., 22, No. 1, 62–68 (2009).CrossRefGoogle Scholar
  6. 6.
    C. Maher, M. Underwood, and R. Buchbinder, “Non-specific low back pain,” Lancet, 389, No. 10070, 736–747 (2017),  https://doi.org/10.1016/S0140-6736(16)30970-9.CrossRefGoogle Scholar
  7. 7.
    A. E. Karateev, D. E. Karateev, and O. S. Davydov, “Pain and inflammation. Part 2. The analgesic potential of anti-inflammatory drugs,” Nauch.-Prakt. Revmatol, 55, No. 1, 58–67 (2017),  https://doi.org/10.14412/1995-4484-2017-58-67.Google Scholar
  8. 8.
    A. E. Karateev, D. S. Novikova, and E. L. Nasonov, “New data on the safety of non-steroidal anti-inflammatory drugs: the concept of the high “class-specific” cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated,” Nauch.-Prakt. Revmatol., 55, No. 2, 218–223 (2017),  https://doi.org/10.14412/1995-4484-2017-218-223.Google Scholar
  9. 9.
    N. N. Knezevic, S. Mandalia, J. Raasch, et al., “Treatment of chronic low back pain – new approaches on the horizon,” J. Pain Res., 10, 1111–1123 (2017); S132769 eCollection 2017,  https://doi.org/10.2147/JPR.
  10. 10.
    D. J. Clauw, “Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s),” Best Pract. Res. Clin. Rheumatol., 29, No. 1, 6–19 (2015),  https://doi.org/10.1016/j.berh.2015.04.024.CrossRefGoogle Scholar
  11. 11.
    R. I. Russell, “Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy,” Ital. J. Gastroenterol. Hepatol., 31, No. 1, 14–18 (1999).Google Scholar
  12. 12.
    F. K. Chan and D. Y. Graham, “Review article: prevention of non-steroidal antiinflammatory drug gastrointestinal complications – review and recommendations based on risk assessment,” Aliment. Pharmacol. Ther., 19, No. 10, 1051–1061 (2004), https://doi.org/ https://doi.org/10.1136/ard.2010.128660.
  13. 13.
    R. W. Dubois, G. Y. Melmed, J. M. Henning, and L. Laine, “Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclooxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy,” Aliment. Pharmacol. Ther., 19, No. 2, 197–208 (2004), https://doi.org/ https://doi.org/10.1111/j.1365-2125.2007.03038.
  14. 14.
    W. C. Tsai, T. T. Ou, J. H. Yen, et al., “Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study,” PLoS One, 10, No. 5, 0126347 (2015), eCollection 2015,  https://doi.org/10.1371/journal.pone.0126347.
  15. 15.
    C. Rafaniello, C. Ferrajolo, M. G. Sullo, et al., “Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system,” Pharmacol. Res., 104, 108–114 (2015),  https://doi.org/10.1016/j.phrs.2015.12.026.CrossRefGoogle Scholar
  16. 16.
    E. Rosen, I. Tsesis, and M. Vered, “US Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal anti-inflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist’s perspective,” Refuat Hapeh Vehashinayim, 32, No. 4, 6–10 (1993).Google Scholar
  17. 17.
    Y. L. Cao, Z. G. Tian, F. Wang, et al., “Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients,” World J. Gastroenterol., 20, No. 38, 13956–13965 (2014),  https://doi.org/10.3748/wjg.v20.i38.13956.CrossRefGoogle Scholar
  18. 18.
    R. Shiri, J. Karppinen, P. Leino-Arjas, et al., “The association between obesity and low back pain: a meta-analysis,” Am. J. Epidemiol., 171, No. 2, 135–154 (2010),  https://doi.org/10.1093/aje/kwp356.CrossRefGoogle Scholar
  19. 19.
    I. Heuch, K. Hagen, I. Heuch, et al., “The impact of body mass index on the prevalence of low back pain: the HUNT study,” Spine (Phila Pa 1976), 35, No. 7, 764–768 (2010),  https://doi.org/10.1097/BRS.0b013e3181ba1531.CrossRefGoogle Scholar
  20. 20.
    L. I. Arranz, M. Rafecas, and C. Alegre, “Effects of obesity on function and quality of life in chronic pain conditions,” Curr. Rheumatol. Rep., 16, No. 1, 390 (2014),  https://doi.org/10.1007/s11926-013-0390-7.CrossRefGoogle Scholar
  21. 21.
    L. Chou, S. R. Brady, D. M. Urquhart, et al., “The Association between obesity and low back pain and disability is affected by mood disorders: A population-based, cross-sectional study of men,” Medicine (Baltimore), 95, No. 15, 3367 (2016),  https://doi.org/10.1097/MD.0000000000003367.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • I. Z. Gaydukova
    • 1
    Email author
  • D. M. Bichurina
    • 2
  • Yu. R. Popova
    • 1
  • A. P. Rebrov
    • 2
  1. 1.Mechnikov North-Western State Medical UniversityRussian Ministry of HealthSt. PetersburgRussia
  2. 2.Razumovskii Saratov State Medical UniversityRussian Ministry of HealthSaratovRussia

Personalised recommendations